MS

Menarini Stemline at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Menarini Stemline takes part in 1 session at ESMO 2026 in Madrid, and exhibits at Booth 8065. Its program centres on advanced breast cancer with ESR1 mutations and the changing options for treating it. The topic ties to elacestrant, its medicine for oestrogen receptor-positive, HER2-negative advanced breast cancer.

OrganizationESMO 2026 Attendance
MS
Menarini Stemline
Large pharmaExhibitor
Oncology business of the Menarini Group, marketing medicines including elacestrant for ER-positive, HER2-negative advanced breast cancer.
Booth
Exhibiting at Booth 8065
Satellite
Fri Oct 23
18:15–19:45
Menarini Stemline - ESR1-mutated Advanced Breast Cancer: A Transforming Treatment Landscape
Sponsored session · with Hospital Universitario 12 de Octubre
Breast cancerBiomarkers & precision oncology

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Menarini Stemline

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction